Skip to content
ContentLora

    Tip: press / anywhere to search.

    Explainer

    The FDA's mifepristone review explained

    In September 2025 the FDA said it would re-examine the 2023 safety rules (the REMS) that let patients get the abortion pill mifepristone without an in-person visit, including by mail.[1][2] In an October 2026 court filing the FDA said it expected to finish a safety study by mid-December 2026 and report no later than March 2027, before deciding on any changes.[3] For now the 2023 rules remain in effect: the Supreme Court has paused a lower-court order that would have halted remote prescribing.[4]

    Editor reviewedStrict sourcingUpdated Explainer9 claims · 100% primaryPregnancy and reproductive health, Health and medicine, Courts and the law

    This page describes regulatory actions and court records as of 2026-11-14 (UTC) and attributes each position to its source. It gives no medical or dosing advice: ask a clinician about your own care. The review and the court cases are moving, so check the dates on each statement.

    The drug and its rules

    The FDA first approved mifepristone, sold as Mifeprex, in 2000 and a generic version in 2019. It is approved, in a regimen with misoprostol, to end an intrauterine pregnancy through ten weeks of gestation.[5] The Congressional Research Service (CRS) notes that, according to CDC data published in 2022, medication abortions make up roughly half of US abortions.[6]

    The drug is sold under a risk evaluation and mitigation strategy (REMS), a set of safety conditions the FDA can attach to a drug. A REMS modification the FDA approved on 3 January 2023 let patients get mifepristone without an in-person visit, including by mail from certified prescribers or pharmacies.[2] For how state abortion laws interact with these rules, see abortion laws explained.

    The review

    In September 2025 the FDA announced it would re-examine the 2023 REMS. According to CRS, the agency said the reconsideration rested on “the lack of adequate consideration underlying the prior REMS approvals” and on recent studies raising concerns about the drug’s safety as currently used. CRS described the review as ongoing in May 2026.[1]

    In a status report filed in the Louisiana case on 7 October 2026, the FDA said it was on track to get the results of a safety study by mid-December 2026 and expected to finish its report “not later than March 2027”, after which it would decide whether changes to the REMS are necessary.[3] The agency said the study uses data from Sentinel, a distributed database, along with a “TreeScan” statistical data-mining analysis, and that its review also covers several pending citizen petitions, including requests to restore requirements such as dispensing only in certain healthcare settings.[7]

    The court cases

    Louisiana v. FDA. In October 2025 Louisiana sued to vacate the 2023 REMS. The Fifth Circuit granted a stay of the rules allowing remote prescribing and dispensing, but the Supreme Court paused that stay while the case continues, so remote prescribing and mail dispensing remain available.[4]

    Suits seeking fewer restrictions. Other plaintiffs argue the REMS is too strict. In a case brought by 17 states and DC, a federal court in Washington sided with the FDA in July 2025. A federal court in Hawaii declared the REMS unlawful but left it in place while the FDA carries out its review.[8]

    Whole Woman’s Health Alliance v. FDA. Abortion providers in Virginia, Kansas and Montana challenged the 2023 REMS as excessively restrictive. On 23 July 2026 a federal judge in the Western District of Virginia held that the FDA had failed to consider relevant evidence and give a reasoned explanation for its 2023 REMS modification, making it arbitrary and capricious. The court said the modification would be remanded to the FDA once the status of the plaintiffs’ constitutional claims is determined.[9]

    What to watch

    The next dates the FDA has given are the end of its safety study, expected by mid-December 2026, and its report, due no later than March 2027.[3] The FDA has said it will decide on any changes after that report. Separately, AP reports that the Supreme Court has blocked changes to the drug in the Louisiana case until it sees that case again.[4]

    More in Reproductive health

    Questions readers ask

    What is the FDA reviewing?

    The 2023 version of mifepristone's risk evaluation and mitigation strategy (REMS), which lets patients get the drug without an in-person visit, including by mail from certified prescribers or pharmacies. The FDA announced the re-examination in September 2025.[2][1]

    Why did the FDA start the review?

    According to CRS, the FDA cited "the lack of adequate consideration underlying the prior REMS approvals" and recent studies raising concerns about the drug's safety as currently used.[1]

    When will the review finish?

    The FDA told a court in October 2026 it expected to complete a safety study by mid-December 2026 and to report findings no later than March 2027, after which it would decide on any changes.[3]

    Can mifepristone still be prescribed by telehealth and mailed?

    Yes, as of the latest reports. The Fifth Circuit granted Louisiana a stay of the remote prescribing rules, but the Supreme Court paused that stay while the case continues.[4]

    Have courts ruled on the 2023 rules?

    In different directions. In suits arguing the rules are too strict, a Washington court sided with the FDA in July 2025; a Hawaii court declared the REMS unlawful but left it in place; and on 23 July 2026 a Virginia court, in a case brought by abortion providers, held that the FDA had not adequately justified its 2023 modification and said it would be sent back to the FDA. Separately, the Louisiana case seeks to undo the 2023 rules.[8][9][4]

    Sources

    · 9 claims from 5 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      In September 2025 the FDA announced it would re-examine the 2023 REMS, citing "the lack of adequate consideration underlying the prior REMS approvals" and recent studies raising safety concerns; CRS described the review as ongoing in May 2026. confirmedas of 2026-05-28

    2. [2]

      A REMS modification the FDA approved on 3 January 2023 let patients obtain mifepristone without an in-person visit, including by mail from certified prescribers or pharmacies. confirmedas of 2026-05-28

    3. [3]

      In a status report filed on 7 October 2026 the FDA said it was on track to get results of its mifepristone safety study by mid-December 2026, expected to finish its report no later than March 2027, and would then decide whether changes to the REMS are needed. confirmedas of 2026-10-07

    4. [4]

      In October 2025 Louisiana sued to vacate the 2023 REMS; the Fifth Circuit granted a stay of the remote prescribing and dispensing rules, but the Supreme Court paused that stay, so remote prescribing and mail dispensing remained available as of October 2026. confirmedas of 2026-10-08

    5. [5]

      The FDA first approved mifepristone (Mifeprex) in 2000 and a generic version in 2019; it is approved, in a regimen with misoprostol, to end an intrauterine pregnancy through ten weeks of gestation. confirmedas of 2025-01-17

    6. [6]

      CRS notes that, according to CDC data published in 2022, medication abortions make up roughly half of US abortions. confirmedas of 2026-05-28

    7. [7]

      The FDA told the court it was using data from its Sentinel distributed database and a "TreeScan" statistical data-mining analysis, and that its REMS review also covers several pending citizen petitions, some seeking to restore the in-person dispensing requirement. confirmedas of 2026-10-07

    8. [8]

      Other suits argue the REMS is too strict; a federal court in Washington sided with the FDA in July 2025 in a case brought by 17 states and DC, while a federal court in Hawaii declared the REMS unlawful but left it in place during the FDA's review. confirmedas of 2026-05-28

    9. [9]

      In a case brought by abortion providers in Virginia, Kansas and Montana who challenged the 2023 REMS as excessively restrictive, a federal judge in the Western District of Virginia held on 23 July 2026 that the FDA had failed to consider relevant evidence and give a reasoned explanation for its 2023 REMS modification, making it arbitrary and capricious, and said the modification would be remanded to the FDA once the status of the plaintiffs' constitutional claims is determined. confirmedas of 2026-07-23

    Revision history (1)
    1. Page created.

    Created Nov 14, 2026. Last reviewed by an editor on Nov 15, 2026. Next scheduled review: Dec 31, 2026.

    Cite this page

    "The FDA's mifepristone review explained." ContentLora, updated Nov 14, 2026. https://contentlora.com/explain/mifepristone-fda-review-2026

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.